Attenuation of insulin secretion by insulin-like growth factor 1 is mediated through activation of phosphodiesterase 3B
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Both insulin and insulin-like growth factor 1 (IGF-1) are known to reduce glucose-dependent insulin secretion from the β cells of pancreatic islets. In this paper we show that the mechanism by which IGF-1 mediates this effect is in large part through activation of a specific cyclic nucleotide phosphodiesterase, phosphodiesterase 3B (PDE3B). More specifically, in both isolated pancreatic islets and insulin-secreting HIT-T15 cells, IGF-1 inhibits insulin secretion that has been increased by glucose and glucagonlike peptide 1 (GLP-1). Moreover, IGF-1 decreases cAMP levels in parallel to the reduction of insulin secretion. Insulin secretion stimulated by cAMP analogs that activate protein kinase A and also are substrates for PDE3B is also inhibited by IGF-1. However, IGF-1 does not inhibit insulin secretion stimulated by nonhydrolyzable cAMP analogs. In addition, selective inhibitors of PDE3B completely block the ability of IGF-1 to inhibit insulin secretion. Finally, PDE3B activity measured in vitro after immunoprecipitation from cells treated with IGF-1 is higher than the activity from control cells. Taken together with the fact that pancreatic β cells express little or no insulin receptor but large amounts of IGF-1 receptor, these data strongly suggest a new regulatory feedback loop model for the control of insulin secretion. In this model, increased insulin secretion in vivo will stimulate IGF-1 synthesis by the liver, and the secreted IGF-1 in turn feedback inhibits insulin secretion from the β cells through an IGF-1 receptor-mediated pathway. This pathway is likely to be particularly important when levels of both glucose and secretagogues such as GLP-1 are elevated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Holz, G. G., Leech, C. A., & Habener, J. F. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.30.17749 · Cited by 188
Cited by
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
“Insulin and IFG-1 increase levels of PDE3B, and treatment of hamster clonal b-cells (HIT-T15) with IGF-1 deteriorates the insulinotropic effect of GLP-1 [486].”
BackgroundCyclic Nucleotide Phosphodiesterases: Molecular Regulation to Clinical Use
Bender, A. T., & Beavo, J. A. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.5 · Cited by 1,781
Self-citationRegulation of cAMP and cGMP signaling: new phosphodiesterases and new functions
Soderling, S. H., & Beavo, J. A. (2000) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(99)00073-3 · Cited by 736
Self-citationMechanisms of action of glucagon-like peptide 1 in the pancreas
Doyle, M. E., & Egan, J. M. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.11.007 · Cited by 680
Kubota, N., Tobe, K., Terauchi, Y., Eto, K., Yamauchi, T., Suzuki, R., Tsubamoto, Y., Komeda, K., Nakano, R., Miki, H., et al. (2000) · Diabetes · doi:10.2337/diabetes.49.11.1880 · Cited by 521
The New Biology and Pharmacology of Glucagon
Müller, T. D., Finan, B., Clemmensen, C., DiMarchi, R. D., & Tschöp, M. H. (2017) · Physiological Reviews · doi:10.1152/physrev.00025.2016 · Cited by 419
“Notably in -cells, insulin and insulin-like growth factor 1 (IGF-1) enhance levels of PDE3B and treatment of hamster clonal -cells (HIT-T15) with IGF-1 substantially lowers GLP-1 induced insulin secretion (676).”
BackgroundIsolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A
Soderling, S. H., Bayuga, S. J., & Beavo, J. A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.12.7071 · Cited by 374
Self-citationLeptin signaling in the hypothalamus: emphasis on energy homeostasis and leptin resistance
Sahu, A. (2003) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2003.10.001 · Cited by 355
Induction of leptin resistance through direct interaction of C-reactive protein with leptin
Chen, K., Li, F., Li, J., Cai, H., Strom, S., Bisello, A., Kelley, D. E., Friedman-Einat, M., Skibinski, G. A., McCrory, M. A., et al. (2006) · Nature Medicine · doi:10.1038/nm1372 · Cited by 325
“After a 30-min incubation with leptin, we harvested the cells with lysis buffe”
MethodSelf-citationCloning and characterization of a cAMP-specific cyclic nucleotide phosphodiesterase
Soderling, S. H., Bayuga, S. J., & Beavo, J. A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.15.8991 · Cited by 271
Self-citationInsulin: The Friend and the Foe in the Development of Type 2 Diabetes Mellitus
Rachdaoui, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051770 · Cited by 265
Cyclic nucleotide phosphodiesterase 3A–deficient mice as a model of female infertility
Masciarelli, S., Horner, K., Liu, C., Park, S. H., Hinckley, M. D., Hockman, S. C., Nedachi, T., Jin, C., Conti, M., & Manganiello, V. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200421804 · Cited by 261
Cyclic nucleotide phosphodiesterases and their role in endocrine cell signaling
Mehats, C., Andersen, C. B., Filopanti, M., Jin, S.-L. C., & Conti, M. (2002) · Trends in Endocrinology & Metabolism · doi:10.1016/s1043-2760(01)00523-9 · Cited by 257
Pharmacological Agents That Directly Modulate Insulin Secretion
Doyle, M. E., & Egan, J. M. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.1.7 · Cited by 256
Insulin-Like Growth Factor 1 (IGF-1) Signaling in Glucose Metabolism in Colorectal Cancer
Kasprzak, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126434 · Cited by 248
Antiobesity Pharmacotherapy: New Drugs and Emerging Targets
Kim, G. W., Lin, J. E., Blomain, E. S., & Waldman, S. A. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.204 · Cited by 191
From PDE3B to the regulation of energy homeostasis
Degerman, E., Ahmad, F., Chung, Y. W., Guirguis, E., Omar, B., Stenson, L., & Manganiello, V. (2011) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2011.09.015 · Cited by 130
Böni-Schnetzler, M., Hauri, C., & Zapf, J. (1999) · Diabetologia · doi:10.1007/s001250051134 · Cited by 45
“Similarly, insulin secretion has been reported to be suppressed by rhIGF I in rat pancreatic islets and islet cells in vitro [36, 37] as well as during shortterm infusion in fasted rats [38].”
Background
Metadata
- Authors
- Zhao, A. Z., Zhao, H., Teague, J., Fujimoto, W., & Beavo, J. A.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1997-04
- Volume
- 94
- Issue
- 7
- Pages
- 3223-3228
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2046406719
- Cited by
- 133
- References
- 1
- FWCI
- 9.95
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.